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High-flow nasal cannula for COVID-19
patients: risk of bio-aerosol dispersion
To the Editor:
We read with interest the article by LI et al. [1] entitled “High-flow nasal cannula for COVID-19 patients:
low risk of bio-aerosol dispersion”, recently published in the European Respiratory Journal. Although we
do agree with the authors that high-flow nasal cannula (HFNC) might be an effective treatment for
hypoxaemic coronavirus disease 2019 (COVID-19) patients, we believe that caution should be taken in
considering HFNC in COVID-19 patients, as data about droplet dispersion and aerosol generation with
HFNC are at least controversial [2]. The authors state that the scientific evidence of generation and
dispersion of bio-aerosols via HFNC is similar to standard oxygen therapies. This statement is mainly
based on the studies of HUI et al. [3] and IP et al. [4], which showed that HFNC led to a smaller
dispersion distance compared to non-rebreather and Venturi masks during exhaled smoke dispersion
experiments. The assumption that the physical extent of exhaled air plumes is equal to the visible extent of
exhaled smoke plumes is wrong: the visibility of smoke rapidly decreases when it mixes with clean air, but
smoke particles do not disappear. In addition to that, the dispersion of small-sized smoke particles and
aerosols is not identical to the dispersion of particles that have a broad range of sizes. These observations
are important when studying the actual spread of viruses.
When a jet escapes from the mask, nose or mouth of a patient during ventilation therapy, virus-carrying
droplets in the jet will follow different trajectories depending on their size. Each droplet of a specific size
has a different terminal velocity, i.e. the vertical velocity that will be reached in quiescent air. Larger
droplets carrying viral parts have a relatively high terminal velocity and will therefore deposit sooner than
smaller droplets [5], which was recently confirmed by SOMSEN et al. [6]. However, patient-emitted aerosols
(droplet diameter <1 μm) are excellent passive tracers just like smoke particles; they have very small
terminal velocities and can end up anywhere before ultimately leaving through the ventilation system.
They also may contain viral parts that may remain viable for at least 3 h [7].
To estimate the dispersion of droplets, we have performed a passive-tracer visualisation using an
anatomically correct 3D-printed head of a male adult, created using data from embodi3D [8], which were
modified with the author’s permission. Normal breathing was simulated, and HFNC and oxygen therapies
were applied. The lung simulator consisted of a P1D-S050MS-0320 pneumatic cylinder (Parker, Cleveland,
OH, USA) driven by a PS01-37Sx120F-HP-N rigidly connected linear motor (LinMot, Spreitenbach,
Switzerland). The applied breathing pattern, mimicking healthy tidal breathing, had a tidal volume of
475 mL and a respiratory rate of 15 breaths·min−1. Smoke was generated using Miniax KS smoke patterns
(Björnax AB, Nora, Sweden), consisting of particles between 0.3 and 2.5 μm, and inserted between the
lung simulator and the 3D-printed head. The reflected light from the exhaled smoke was recorded using
two cameras, and by combining these images, the extent of the exhaled air/smoke plumes was determined.
From the distance and corresponding travelling time, air velocities during different therapies were
estimated. Given the terminal velocity of 25 cm·s−1 for droplets with a diameter of 100 µm (based on the
theory of FLAGAN and SEINFELD [5]) and assuming a typical height of the patient’s nose compared to
neighbouring surfaces of 10 cm, a rough estimate of the dispersion range of large (100 µm) droplets was
obtained. The results are shown in table 1.
Our experiments show that the calculated air velocity during HFNC is larger than during oxygen therapies.
Thus, the estimated dispersion distance of large droplets is also larger during HFNC compared to standard
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HFNC seems to increase droplet spread, so caution should be taken if it is applied for COVID-19, and
adequate protective measures should be provided. Further research on viral spread and risks associated
with HFNC therapy in COVID-19 patients is needed. https://bit.ly/3gQjjrY
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oxygen masks. Furthermore, the maximum range of visible smoke concentrations at the end of exhalation is
larger during HFNC than during oxygen therapies, which contradicts the results of HUI et al. [3].
Due to the clear limitations of this relatively simple experiment, the aim is not to provide exact distances
and velocities, but rather to gain awareness for the increased velocity levels of exhaled air during HFNC
compared to other oxygen therapies, especially at higher flow rates. This strongly suggests that larger
droplets are more widely dispersed by HFNC therapy than by other oxygen therapies.
We do believe that HFNC can be considered as a therapy for COVID-19 patients, but, if applied, caution
should be taken and adequate protective measures should be provided [9]. It is quite clear that further
research on viral spread and risks associated with HFNC therapy in COVID-19 patients is mandatory.
Judith Elshof 1,2, Rutger H.J. Hebbink3, Marieke L. Duiverman 1,2 and Rob Hagmeijer3
1Dept of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center
Groningen, Groningen, The Netherlands. 2Groningen Research Institute for Asthma and COPD (GRIAC), University of
Groningen, Groningen, The Netherlands. 3Engineering Fluid Dynamics, University of Twente, Enschede,
The Netherlands.
Correspondence: Judith Elshof, Dept of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen,
University Medical Center Groningen, Hanzeplein 1, Groningen, The Netherlands. E-mail: j.elshof@umcg.nl
Received: 02 Aug 2020 | Accepted: 05 Aug 2020
Conflict of interest: J. Elshof reports grants from Vivisol BV and Fisher and Paykel Ltd, outside the submitted work.
R.H.J. Hebbink reports grants and non-financial support from Fisher and Paykel Healthcare, outside the submitted
work. M.L. Duiverman reports grants from Philips BV, Vivisol BV, and Fisher and Paykel Ltd, and grants and personal
fees from Resmed Ltd, outside the submitted work. R. Hagmeijer has nothing to disclose.
References
1 Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur
Respir J 2020; 55: 2000892.
2 Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients
with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection
transmission. Can J Anaesth 2020; 67: 1217–1248.
3 Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via
different masks. Eur Respir J 2019; 53: 1802339.
4 Ip M, Tang JW, Hui DSC, et al. Airflow and droplet spreading around oxygen masks: a simulation model for
infection control research. Am J Infect Control 2007; 35: 684–689.
5 Flagan RC, Seinfeld JH. Fundamentals of Air Pollution Engineering. Englewood Cliffs, Prentice-Hall, 1988.
6 Somsen GA, van Rijn C, Kooij S, et al. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2
transmission. Lancet Respir Med 2020; 8: 658–659.
TABLE 1 Dispersion distances of exhaled smoke with visible concentration, and velocities and
















Small cannula 30 71.2 0.65 26.2
Small cannula 60 72.1 0.83 33.4
Medium
cannula
30 33.9 0.64 25.5
Medium
cannula
60 48.5 0.63 25.4
Large cannula 30 25.4 0.47 18.8
Large cannula 60 73.3 0.72 28.8
Non-rebreather
mask
15 20.3 0.38 15.1
Venturi mask
FIO2 0.4 10 22.0 0.23 9.1
FIO2 0.6 15 33.7 0.26 10.3
HFNC: high-flow nasal cannula; FIO2: inspiratory oxygen fraction.
#: dispersion range of large droplets was
estimated based on the air velocity at 0.5 s after start of expiration.
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